On June 22, 2023 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that the first patient has been dosed in the triple immunotherapy combination proof-of-concept study evaluating COM701, Compugen’s potential first-in-class anti-PVRIG antibody, with COM902, Compugen’s potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer (Press release, Compugen, JUN 22, 2023, View Source [SID1234632843]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very excited that the first patient with platinum resistant ovarian cancer has been dosed with the triple immunotherapy combination of COM701, COM902 and pembrolizumab in our proof-of-concept study. This milestone keeps us on track to report initial findings by the end of this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "The goal of the study is to build on the encouraging data previously reported by us at the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress 2022, with the dual and triple blockade of PVRIG and PD-1 with or without TIGIT. We expect that this study will help us to better understand the contribution of the components and contribute to our ongoing biomarker work to try and identify the patients most likely to respond, with the purpose of building a path to registration."
"Despite recent advances in the treatment of patients with platinum resistant ovarian cancer, there remains a significant unmet need for new treatment options for these patients," said Dr. Manish Sharma, Associate Director of Clinical Research at START Midwest in Grand Rapids, Michigan. "I am very excited to participate in this proof-of-concept study with the novel triple immunotherapy combination of COM701, COM902 and pembrolizumab. Our initial observation is that this combination is well tolerated by patients as observed in our microsatellite stable colorectal cancer proof-of-concept study initiated recently. I hope this differentiated approach of blocking three pathways in the DNAM-1 axis, PVRIG, TIGIT and PD-1 will result in additional treatment options for patients with platinum resistant ovarian cancer."
Details on the study:
This proof-of-concept study (NCT04354246) is an open label study evaluating the combination of COM701 with COM902 and pembrolizumab in up to 40 patients with high grade platinum resistant epithelial ovarian cancer including patients with fallopian tube cancer and primary peritoneal cancer who have received up to 3 lines of prior therapy for platinum resistant ovarian cancer. The study includes patients with all histologies. The initiation of the study is based on Phase 1 cohort expansion data reported at ESMO (Free ESMO Whitepaper)-IO 2022, showing a favorable safety and tolerability profile and durable anti-tumor activity with the combination of COM701 and nivolumab ± BMS-986207 in platinum resistant ovarian cancer patients.